Skip to main content
OpenTrials
Completed

NCT Number: NCT00266760

Characteristics of Episodic Ataxia Syndrome

Episodic ataxia (EA) is a rare genetic disease characterized by episodes of imbalance, incoordination, and slurring of speech. The underlying cause of EA is only partly understood, and currently there are no established treatments. There is also little information about the link between EA's clinical features and its genetic basis. The purpose of this study is to better characterize EA and disease progression. In turn, this may direct the development of future treatments.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

London Health Sciences Centre, London, Ontario, Canada

Loading trial locations.

About this study

Attacks of ataxia, or the loss of ability to coordinate muscular movement, are often triggered by stress or exertion. EA is likely caused by an inherited genetic mutation; many individuals with EA have abnormalities in the KCNA1 or CACNA1A genes. To date, two known subtypes of EA have been identified, and other types likely exist. Specific characteristics of each EA subtype, however, have not been adequately described. The purpose of this study is to better define the clinical features and genetic basis of the various subtypes of EA and to evaluate disease progression. The study will also establish relevant study endpoints for use in future therapeutic trials.

This multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. Participants will initially attend an outpatient study visit that will last 7 hours. This initial evaluation will include a medical history, a physical examination, neurological testing, and an ataxia assessment. Blood will be collected for genetic testing. Additionally, the following procedures may be conducted: ocular motor test, electromyography/nerve conduction study, electroencephalogram, MRI, and digital videotaping. Follow-up evaluations will occur on a yearly basis for at least 2 years; each will last 4 hours.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A clinically confirmed diagnosis of episodic ataxia as defined by one of the following three features:
  • Clear-cut episodes of recurrent, transient ataxia
  • Mutation confirmed in KCNA1 or CACNA1A
  • Ataxic features with a first degree relative with episodic ataxia

Exclusion criteria

  • Any other disorder known to cause episodic ataxia

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Collaborators

  • Office of Rare Diseases (ORD)
  • Rare Diseases Clinical Research Network

Registry information

Official study title

Episodic Ataxia Syndrome: Genotype-phenotype Correlation and Longitudinal Study

Important dates

Study start
2006
Primary completion
2011
Study completion
2011
First posted
Dec 19, 2005
Registry last updated
May 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.